Skip to contentA
Aptevo Therapeutics Inc.
A
APVOAptevo Therapeutics Inc. Q3 2019 · 10-Q
Revenue$9.01M$9.01M+54.7% vs Q3 2018 Net Income-$6.92M-$6.92MN/M vs Q3 2018 EPS Diluted-$2.15-$2.15N/M vs Q3 2018 Operating Income-$11,459,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,548,000N/M Margins · derivedOperating margin-127.2%+81.1 pt vs Q3 2018
Net margin-76.8%+138.9 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 7, 2019 · 38 d after period end